Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341560 · ClinicalTrials.gov registry record · Phase 2
Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
A Phase 2 study, sponsored by Quark Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 732
- Enrollment target
NCT02341560: Clinical Trial Phase 2 study, sponsored by Quark Pharmaceuticals.
NCT02341560 is a Phase 2 study that was terminated before completion, run by Quark Pharmaceuticals. The registered enrollment target is 732 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (450% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02341560, a Phase 2 study, was terminated before completion, sponsored by Quark Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 732 participants
- Enrollment target
Study Summary
This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population. This study will also evaluate the structural changes in the retina following administration of QPI-1007.
Interventions
- DRUG QPI-1007 Injection - 1.5 mg
- DRUG QPI-1007 Injection - 3.0 mg
- OTHER Sham Injection Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 2016-02-24 |
| Est. Completion | 2019-07-01 |
| Phase | Phase 2 |
Why NCT02341560 stopped before completion
NCT02341560 is an interventional study that assigns participants to a tested intervention. The registered 732 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (450% higher).
The record links to 0 conditions, and to 3 interventions - of which QPI-1007 Injection - 1.5 mg is the first listed.
NCT02341560 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02341560 about?
NCT02341560 is a clinical study titled "Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)". This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population. This study will also evaluate the structural changes in the retina following administration of QPI...
What is the current status of trial NCT02341560?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 732 participants. The study started on 2016-02-24. Estimated completion is 2019-07-01.
What interventions are being tested in trial NCT02341560?
The interventions under investigation include: QPI-1007 Injection - 1.5 mg (DRUG), QPI-1007 Injection - 3.0 mg (DRUG), Sham Injection Procedure (OTHER).
Who is sponsoring clinical trial NCT02341560?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02341560's enrollment target sits among peer trials
732 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI